Illumina to Announce Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 5, 2026
Rhea-AI Summary
Illumina (NASDAQ:ILMN) will release fourth quarter and full year 2025 financial results after market close on Thursday, February 5, 2026.
Management will host a conference call at 1:30 PM PT / 4:30 PM ET on the same day. Investors can access a live webcast via the company's Investor Info website or the provided link. A replay will be posted on the website and remain available for at least 30 days.
Positive
- None.
Negative
- None.
News Market Reaction – ILMN
In the Jan 13 session, ILMN gained 0.99%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 06 | Product software launch | Positive | +4.1% | Launch of Illumina Connected Multiomics cloud-based analysis platform. |
| Dec 16 | Investor conference | Neutral | -1.5% | Announcement of J.P. Morgan Healthcare Conference presentation webcast. |
| Dec 11 | Collaboration deal | Positive | +1.1% | Collaboration and strategic investment in MyOme to support MPH Trial. |
| Dec 11 | Correction notice | Neutral | +1.1% | Correction to prior MyOme collaboration and MPH trial announcement. |
| Nov 12 | Scientific study | Positive | -0.5% | Nature study showing WGS captures ~90% of genetic signal in diseases. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has often been positive on products, collaborations, and research, with mixed price reactions—several aligned upward but some scientific or event updates saw modest sell-offs.
Over the last few months, Illumina highlighted multiple strategic and scientific milestones. On Nov 12, 2025, a Nature study underscored whole‑genome sequencing advantages. In Dec 2025, Illumina announced and then corrected details of a collaboration and strategic investment in MyOme’s MPH Trial, citing potential savings of more than $200 billion annually. On Jan 6, 2026, it launched Illumina Connected Multiomics software. The current earnings-date announcement follows this sequence of product, collaboration, and scientific updates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.
Conference Call Details
The conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Thursday, February 5, 2026. Interested parties may access the live webcast via the Investor Info section of Illumina's website or directly through the following link - https://illumina-earnings-call-q4-2025.open-exchange.net. To ensure timely connection, please join at least ten minutes before the scheduled start of the call.
A replay of the conference call will be posted on Illumina's website after the event and will be available for at least 30 days following.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and connect with us on X (Twitter), Facebook, LinkedIn, Instagram, TikTok, and YouTube.
Investors:
Conor McNamara
+1.858.291.6421
ir@illumina.com
Media:
Christine Douglass
pr@illumina.com
View original content:https://www.prnewswire.com/news-releases/illumina-to-announce-fourth-quarter-and-full-year-2025-financial-results-on-thursday-february-5-2026-302658954.html
SOURCE Illumina, Inc.